Biocept's Liquid Biopsy Lung Cancer Target Selector Assay to be featured at World Conference on Lung Cancer
Clinical Data Shows Assay's Utility in Therapeutic Management of Patients with Non-Small Cell Lung Cancer
"Results of our study indicate that the non-invasive Target Selector™
assay could have a role in managing patients with metastatic lung
cancer," said
"These study data further build on clinical evidence that the Target
Selector™affords non-invasive profiling of a tumor's genomic
landscape by monitoring treatment response and early detection of the
emergence of resistance," said
"Further, the Target Selector™ is performed on a simple blood sample
which is also known as a liquid biopsy. Liquid biopsies are used when
the initial diagnostic tissue biopsy sample is depleted, which can occur
as much as 20% of the time. These patients are often too sick for
additional invasive tissue sampling or refuse another surgical
procedure. In addition, our liquid biopsy tests provide cost savings
when compared with surgical tissue biopsies, thus delivering an added
economic benefit to the healthcare system in general," added
About the
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to the role of our assay in
managing patients with metastatic lung cancer, our ability to validate
the use of liquid biopsies for targeted therapies, the ability to
identify indicators of resistance to therapy, improvement of outcomes,
our impact on diagnostic strategies and healthcare costs and planned
future offerings, such statements are forward-looking, and are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements are
subject to numerous risk factors as set forth in our
View source version on businesswire.com: http://www.businesswire.com/news/home/20150908005395/en/
Investors:
LHA
jcain@lhai.com
Source:
News Provided by Acquire Media